XML 77 R66.htm IDEA: XBRL DOCUMENT
v3.25.3

Contingencies (Details) $ in Millions |  |  | 1 Months Ended | 2 Months Ended | 5 Months Ended | 9 Months Ended |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 24, 2025 patent | Mar. 13, 2025 | Nov. 30, 2025 patent | Dec. 31, 2023 case | Jul. 31, 2023 motion | Jun. 30, 2023 | May 31, 2023 patent | Oct. 31, 2025 patent interest_rate_swap | Oct. 31, 2024 patent | Sep. 30, 2025 USD ($) case plaintiff company | Sep. 19, 2025 | Jul. 11, 2025 plaintiff | Jun. 02, 2025 patent | May 01, 2025 plaintiff | Apr. 07, 2025 | Mar. 21, 2025 plaintiff | Mar. 11, 2025 case | Dec. 31, 2024 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of plaintiffs in complaint | plaintiff |  |  |  |  |  |  |  |  |  |  |  | 6 |  | 6,000,000 |  | 7,000,000 |  |
Loss contingency, joint stipulation response period |  |  |  |  |  |  |  |  |  |  | 15 days |  |  |  | 14 days |  |  |
Legal Defense Costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal defense costs reserve | $ |  |  |  |  |  |  |  |  |  | $ 220 |  |  |  |  |  |  |  | $ 225
Pending Litigation | Commercial and Other Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | plaintiff |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |
Loss contingency, number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |
Pending Litigation | Patents - PGR Petition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed | 12 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. | Settled Litigation | Qui Tam |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, new claims filed, number | motion |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Dr. Scholl's | U.S. | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | case |  |  |  |  |  |  |  |  |  | 605 |  |  |  |  |  |  |  |
Gardasil/Gardasil 9 | U.S. | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | case |  |  |  |  |  |  |  |  |  | 135 |  |  |  |  |  |  |  |
Gardasil/Gardasil 9 | U.S. | Motion for Summary Judgement Granted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | case |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16 |
Gardasil/Gardasil 9 | Non-US | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | case |  |  |  |  |  |  |  |  |  | 15 |  |  |  |  |  |  |  |
Zetia | U.S. | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of cases remanded | case |  |  |  | 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bridion | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, claims settled, number of companies | company |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |
Bridion | Settled Litigation | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patent extension, term |  | 5 years |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |
Pediatric exclusivity, term |  | 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Januvia, Janumet, Janumet XR | Settled Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, companies settled with, minimum number | company |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |
Keytruda | Patents | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of appeals issued |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Loss contingency, number of possible appeals | interest_rate_swap |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |
Keytruda | Patents | Forecast |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Keytruda | Pending Litigation | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed |  |  |  |  |  |  | 9 |  | 9 |  |  |  |  |  |  |  |  |
Keytruda | Pending Litigation | Patents | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional patents unpatentable |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |
Subcutaneous Pembrolizumab | Pending Litigation | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |
Loss contingency, number of patents allegedly infringed | 15 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subcutaneous Pembrolizumab | Pending Litigation | Patents - PGR Petition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |  |  |  |
Subcutaneous Pembrolizumab | Pending Litigation | PGR Petition Process, Ineligible to be Challenged |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, pending claims | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Loss Contingency, Claims Settled, Number Of Companies + References No definition available. + Details
Name: | mrk_LossContingencyClaimsSettledNumberOfCompanies
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Companies Settled With, Minimum Number + References No definition available. + Details
Name: | mrk_LossContingencyCompaniesSettledWithMinimumNumber
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Joint Stipulation Response Period + References No definition available. + Details
Name: | mrk_LossContingencyJointStipulationResponsePeriod
Namespace Prefix: | mrk_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Motion For Summary Judgements Granted, Number + References No definition available. + Details
Name: | mrk_LossContingencyMotionForSummaryJudgementsGrantedNumber
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Number Of Cases Remanded + References No definition available. + Details
Name: | mrk_LossContingencyNumberOfCasesRemanded
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Unpatentable, Number + References No definition available. + Details
Name: | mrk_LossContingencyPatentsUnpatentableNumber
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Unpatentable, Number Of Appeals Issues + References No definition available. + Details
Name: | mrk_LossContingencyPatentsUnpatentableNumberOfAppealsIssues
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Unpatentable, Number Of Possible Appeals + References No definition available. + Details
Name: | mrk_LossContingencyPatentsUnpatentableNumberOfPossibleAppeals
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Plaintiffs In Complaint + References No definition available. + Details
Name: | mrk_NumberOfPlaintiffsInComplaint
Namespace Prefix: | mrk_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Patent Extension, Term + References No definition available. + Details
Name: | mrk_PatentExtensionTerm
Namespace Prefix: | mrk_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pediatric Exclusivity, Term + References No definition available. + Details
Name: | mrk_PediatricExclusivityTerm
Namespace Prefix: | mrk_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LitigationReserve
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mrk_CommercialAndOtherLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mrk_PGRPetitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mrk_QuiTamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Dr.SchollsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=mrk_MotionForSummaryJudgementGrantedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaJanumetJanumetXRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SubcutaneousPembrolizumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mrk_PGRPetitionProcessIneligibleToBeChallengedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |